Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Annovis Bio News

    18,01 $ +32,43% +4,41 $
    In : 16,843 € | 26.04.24 22:10:00 NYSE aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A2PNH2
    ISIN: US03615A1088
    US-Symbol: ANVS
    Typ: Aktie

    Annovis Bio News

    04.05.22 - Newsfile
    Annovis Bio Announces First Quarter 2022 Results and Provides Corporate Update
    Berwyn, Pennsylvania--(Newsfile Corp. - May 4, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-​stage drug platform company addressing ...
    28.04.22 - Newsfile
    Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging
    Collaboration to Develop Pharmacodynamic Biomarkers for Buntanetap
    11.04.22 - Newsfile
    Annovis Bio to Participate in World Parkinson's Day to Raise Awareness on the Debilitating Disease
    Berwyn, Pennsylvania--(Newsfile Corp. - April 11, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-​stage drug platform company addressing ...
    23.03.22 - Newsfile
    Annovis Bio to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
    Berwyn, Pennsylvania--(Newsfile Corp. - March 23, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-​stage drug platform company addressing ...
    18.03.22 - Newsfile
    Annovis Bio Presents at International Conference on Alzheimer's & Parkinson (AD/PD 2022)
    Company Provides Update on Clinical Trial Design of Upcoming Phase 3 Clinical Trials in Parkinson's Disease on March 20, 2022
    08.03.22 - Newsfile
    Annovis Bio Announces Presentation at International Conference on Alzheimer's & Parkinson's Diseases 2022
    Presentation will Showcase Trial Design in Upcoming Phase 3 Trial in Parkinson's Disease
    03.03.22 - Newsfile
    Annovis Bio to Present at the Cowen 42nd Annual Health Care Conference
    Berwyn, Pennsylvania--(Newsfile Corp. - March 3, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-​stage drug platform company addressing ...
    25.01.22 - Newsfile
    Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease
    FDA gives guidance for two Phase 3 clinical trials of Buntanetap in Parkinson's Disease
    10.01.22 - Newsfile
    Annovis Bio Enhances Leadership Team with Two Senior Appointments
    Company Appoints Eve Damiano, MS, RAC, as Senior Vice President of Regulatory Operations
    05.01.22 - Newsfile
    Annovis Bio Announces Official Unique Name Buntanetap for Lead Candidate ANVS401
    Berwyn, Pennsylvania--(Newsfile Corp. - January 5, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-​stage drug platform company addressing ...
    03.01.22 - Newsfile
    Annovis Bio to Participate in the Biotech Showcase and H.C. Wainwright Bioconnect Virtual Conferences
    Company to Conduct Virtual One-​on-One Meetings During Biotech Showcase
    20.12.21 - Newsfile
    Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
    Berwyn, Pennsylvania--(Newsfile Corp. - December 20, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-​stage drug platform company ...
    14.12.21 - Newsfile
    Annovis Bio Announces Publication of ANVS401 Mechanism of Action in Peer-Reviewed Pharmaceutics
    ANVS401 (Posiphen) Inhibits the Translation of mRNAs of Neurotoxic Proteins Responsible for the Progression of Neurodegenerative Diseases
    12.07.21 - PR Newswire
    Thinking about trading options or stock in Celldex Therapeutics, Tesla, Prothena Corp, Microsoft, or Annovis Bio?
    Thinking about trading options or stock in Celldex Therapeutics, Tesla, Prothena Corp, Microsoft, or Annovis Bio? PR Newswire
    23.06.21 - The Motley Fool
    Diese 2 Biotech-Aktien sind dieses Jahr um 1.000 % gestiegen
    Zuletzt gab es viele Berichte darüber, dass eine neue Behandlung der Alzheimer-​Krankheit (Alzheimer Disease, kurz AD) entwickelt wird. Dabei können die enormen Gewinne ...
    19.06.21 - The Motley Fool
    Statt Biogen-Aktie: Hier sind 2 bessere Alzheimer-Investments
    Als die amerikanische Aufsichtsbehörde für Lebens- und Arzneimittel (FDA) den Wirkstoff Aducanumab von Biogen (WKN: 789617) zur Behandlung der Alzheimer-​Krankheit ...
    21.05.21 - PR Newswire
    Thinking about buying stock in Annovis Bio, Meten Edtechx Education, Onconova Therapeutics, General Electric, or AMC Entertainment?
    Thinking about buying stock in Annovis Bio, Meten Edtechx Education, Onconova Therapeutics, General Electric, or AMC Entertainment? PR Newswire
    25.08.20 - ACCESSWIRE
    Annovis Bio to Present at The LD 500 Virtual Conference
    LOS ANGELES, CA / ACCESSWIRE / August 25, 2020 / Annovis Bio Inc. (NYSE American:ANVS), a clinical-​stage drug platform company addressing Alzheimer's disease (AD), ...

    Newssuche

    Videos

    newspaper
    26.04.24 +6,31%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »